Medpace Holdings Inc (NASDAQ:MEDP) CFO Jesse J. Geiger sold 14,400 shares of the company’s stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $82.00, for a total transaction of $1,180,800.00. Following the sale, the chief financial officer now owns 16,948 shares of the company’s stock, valued at $1,389,736. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
MEDP stock traded up $2.86 during trading on Wednesday, hitting $89.13. 275,449 shares of the stock traded hands, compared to its average volume of 186,667. The firm’s 50 day moving average is $81.50 and its two-hundred day moving average is $76.86. The company has a debt-to-equity ratio of 0.07, a current ratio of 0.80 and a quick ratio of 0.80. The stock has a market cap of $3.11 billion, a price-to-earnings ratio of 34.41, a price-to-earnings-growth ratio of 2.02 and a beta of 1.50. Medpace Holdings Inc has a 1 year low of $50.14 and a 1 year high of $89.49.
Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $0.71 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.71. The firm had revenue of $216.20 million for the quarter, compared to the consensus estimate of $217.14 million. Medpace had a net margin of 11.35% and a return on equity of 17.06%. The business’s quarterly revenue was up 20.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.67 EPS. As a group, analysts anticipate that Medpace Holdings Inc will post 2.92 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Pearl River Capital LLC bought a new position in shares of Medpace in the 2nd quarter worth approximately $27,000. Ladenburg Thalmann Financial Services Inc. lifted its stake in shares of Medpace by 53.9% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 605 shares of the company’s stock worth $40,000 after purchasing an additional 212 shares during the period. Advisor Group Inc. lifted its stake in shares of Medpace by 18.7% in the 2nd quarter. Advisor Group Inc. now owns 1,462 shares of the company’s stock worth $95,000 after purchasing an additional 230 shares during the period. Marshall Wace LLP bought a new position in shares of Medpace in the 1st quarter worth approximately $99,000. Finally, Patriot Financial Group Insurance Agency LLC bought a new position in shares of Medpace in the 2nd quarter worth approximately $110,000. 78.97% of the stock is currently owned by hedge funds and other institutional investors.
A number of research firms have recently weighed in on MEDP. ValuEngine downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Zacks Investment Research downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Finally, BidaskClub raised shares of Medpace from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, December 24th. Three equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Medpace has a consensus rating of “Buy” and a consensus price target of $77.00.
About Medpace
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
